All News
Filter News
Found 406 articles
-
Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death
8/8/2023
Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the publication of preclinical research with IGV-001 in Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC).
-
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
7/26/2023
IMV Inc. (the “ Company ” or “ IMV ”), recently announced an update on the Sales and Investment Solicitation Process (the “ SISP ”) implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the “ CCAA ”).
-
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
7/25/2023
QuidelOrtho Corporation announced that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2023 IMV ServiceTrak Awards for the sixth consecutive year.
-
IMV announces the first wave of 2023 IMV ServiceTrak™ Clinical Laboratory Awardees at AACC 2023
7/25/2023
Today IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, announced the first wave of category winners of the 2023 IMV ServiceTrak™ Clinical Laboratory Awards.
-
hC Bioscience Appoints Heather Hirsch, Ph.D. as SVP of Translational Science and Cancer Biology, Strengthening Leadership Team in Advancing tRNA-Based Therapeutics
7/18/2023
hC Bioscience, a pioneering biotech company dedicated to advancing tRNA-based therapeutics, has appointed Heather Hirsch, Ph.D., as the Senior Vice President of Translational Science and Cancer Biology.
-
SUSTAINEXT PROJECT: SHOWCASING A NEXT-GENERATION, ZERO-WASTE, DYNAMIC MODEL OF BIOREFINERY FROM EXTREMADURA TO THE BIO-BASED INDUSTRY IN THE EU
6/21/2023
The first European-funded CBE flagship for botanical extract manufacturing
-
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
6/21/2023
InflaRx N.V. announced today the commercial launch of Gohibic (vilobelimab) in the U.S.
-
Shimadzu Medical Systems USA receives an IMV ServiceTrak Award in the General X-ray category
6/5/2023
Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, receives an IMV ServiceTrak Award in the General X-ray Systems category.
-
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
5/11/2023
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three months ended March 31, 2023, and provided a business update.
-
KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors
5/10/2023
KaliVir Immunotherapeutics, Inc. today announced the appointment of Grant McFadden , Ph.D., to its Board of Directors.
-
IMV Receives NASDAQ Delisting Notice
5/8/2023
IMV Inc. announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110 and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act.
-
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
5/1/2023
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors.
-
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4/4/2023
InflaRx N.V. (Nasdaq: IFRX) today announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).
-
Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results
4/4/2023
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies, a company aiming to revolutionize acute respiratory care, announced its financial results for the fourth quarter and year ended December 31, 2022.
-
Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma
3/27/2023
Imvax, Inc. today announced dosing of the first patient in the company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).
-
IMV Inc. Announces Changes to Its Board of Directors
3/27/2023
IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors of the Company, effective immediately.
-
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
3/16/2023
IMV Inc. today announced alongside the release of its fourth quarter and annual results that it has engaged Stonegate Healthcare Partners, L.L.C (“Stonegate”) to explore strategic alternatives following a review of its business.
-
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
3/9/2023
IMV Inc. today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.
-
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
2/21/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.
-
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
2/13/2023
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”) today announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (“MVP-S”), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”).